Table 1.
Pharmaceutical excipient based paclitaxel nanoformulation | ||||||||
---|---|---|---|---|---|---|---|---|
Pharmaceutical excipienta |
Particle size (nm) |
Zeta Potential (mV) |
Fluorescence quenching | Mean fluorescence intensity (MFI×105)c |
% hemolysis at 50 µgd |
|||
Dye quenching (AUC×106)b |
Number of Binding site(s) |
Binding rate constant (k) |
MDA-MB- 231 |
MCF7 | ||||
Aquaplex® | 355.93±15.97 | −4.32±0.81 | 1.65 | 0.80 | 0.003 | 1.37±0.092 | 0.86±0.014 | 2.06±0.01 |
L-Ascorbic acid (L-AC) |
321.63±23.22 | −2.25±0.65 | 0.94 | 1.38 | 0.035 | 1.87±0.031 | 0.98±0.010 | 3.78±0.34 |
Citric acid (CA) | 323.60+27.90 | −3.60±0.65 | 1.17 | 0.57 | 0.008 | 0.23±0.002 | 0.40±0.002 | 50.17±0.35 |
Trappsol®, (CarboxyMethyl- β-CD) |
252.50±14.51 | −6.98±0.78 | 1.26 | 0.73 | 0.012 | 2.18±0.045 | 2.18±0.067 | 7.21±0.59 |
β-cyclodextrin (β-CD) |
254.31±7.58 | −5.07±0.66 | 1.34 | 1.05 | 0.012 | 0.49±0.008 | 0.32±0.004 | 12.71±0.68 |
Hydroxypropyl β- cyclodextrin (HP- β-CD) |
213.56±8.55 | −5.59±0.46 | 1.47 | 0.94 | 0.010 | 0.47±0.004 | 0.18±0.001 | 19.24±3.82 |
D-Mannitol (DM) | 308.33±19.77 | −8.87±0.46 | 1.50 | 0.41 | 0.001 | 0.27±0.001 | 0.23±0.013 | 1.03±0.03 |
D-Sorbitol (DS) | 149.76±4.61 | −7.05±0.30 | 2.58 | 0.63 | 0.001 | 0.14±0.026 | 0.14±0.017 | 6.18±0.59 |
Tannic acid (TA) | 102.22±14.05 | −8.85±0.44 | 0.94 | 1.40 | 0.038 | 4.24±0.045 | 4.91±0.030 | 5.15±0.02 |
D-α-tocopherol (D-α-TP) |
161.06±21.25 | −6.28±0.05 | 1.70 | 0.46 | 0.003 | 0.18±0.001 | 0.21±0.004 | 9.96±0.34 |
Tween 80 (T80) | 80.68±7.13 | −6.63±0.39 | 2.20 | 0.43 | 0.001 | 2.30±0.266 | 2.49±0.149 | 9.96±0.02 |
5 mg/mL of each pharmaceutical excipient was used to generate PE-PTX nanoparticles.
Oregon green 488 conjugated to PTX (5 µg/ml) was quenched with 130 µg/ml of PE solutions.
Coumarin 6 loaded Pharmaceutical excipient nanoparticles (5 μg/ml equivalent coumarin 6 nanoparticles) were treated on breast cancer cells
ASTM E2524–08 standard considers hemolysis of ≤ 5% safe compounds are safe for human consumption.